About Hadean Ventures
Hadean Ventures is a venture capital firm founded in 2014. It is primarily based out of Oslo, Norway. As of Sep 2026, Hadean Ventures is an active investor, having invested in 21 companies, with 1 new investment in the last 12 months. It primarily invests in Series A round in Sweden based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and High Tech. Most recently it participated in the $***** Series C round of Kasvu Therapeutics Overall, Hadean Ventures portfolio has seen 2 IPOs and 5 acquisitions including key companies like Saga Diagnostics, Galecto Biotech and Oncoinvent. A lot of funds co-invest with Hadean Ventures, with names like Sunstone sharing a substantial percentage of its portfolio. Hadean Ventures has team of 13 people including 4 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Rounds of Entry
Series A, Series B & 5 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Hadean Ventures' List of Top Investments
Hadean Ventures has a portfolio of 21 companies. Their most notable investments are in Attgeno and Saga Diagnostics.Their portfolio spans across Sweden, Germany, Norway and 8 more locations. They have invested in Life Sciences, HealthTech, High Tech and 2 other sectors, across stages such as Series A, Series B and 5 more. Here is the list of top investments by Hadean Ventures:Provider of tests for detection and analysis of circulating tumor DNA. It uses next-generation sequencing and proprietary algorithms to detect the presence of cell-free tumor DNA in the blood. The products include SAGAsafe, SAGAsign, and SAGAseq to detect mutations and to measure the therapeutic effect. In addition, the company also provides services for the analysis of gene and chromosomal mutations.
Key facts about Saga Diagnostics
- Founded Year: 2016
- Location: Morrisville (United States)
- Annual Revenue: $1M - $10M as on Dec 31, 2022
- Stage: Acquired
- Total Funding till date: $17.9M
- Employee Count: 85 as on Aug 31, 2026
- Investors: Hadean Ventures, EIC Fund and 11 Others
- Latest Funding Round: Series A, Jun 29, 2021, $*****
- Highlight: Acquired
Developer of gene therapies to treat retinal diseases. The company's product line include CTx001 an AAV-based gene therapy for the targeted treatment of Geographic Atrophy due to dry age-related macular degeneration.
Key facts about Complement Therapeutics
- Founded Year: 2020
- Location: London (United Kingdom)
- Valuation: $*****
- Stage: Series A
- Total Funding till date: $84.8M
- Employee Count: 36 as on Aug 31, 2026
- Investors: Hadean Ventures, Cambridge Innovation Capital and 7 Others
- Latest Funding Round: Series A, Apr 17, 2023, $*****
- Highlight: Editors' Pick
Galecto Biotech is a clinical-stage biopharma developing galectin modulators for idiopathic pulmonary fibrosis and other severe diseases, including fibrosis and cancer. It has developed ultra-potent galectin-3 inhibitors that specifically block the binding of galectin-3 to carbohydrate structures. The lead candidate, TD-139, completed Phase Ib/IIa trials. TD139 is a highly potent, specific inhibitor of the galactoside binding pocket of galectin-3. TD139 was initially developed by a team.
Key facts about Galecto Biotech
- Founded Year: 2010
- Location: Copenhagen (Denmark)
- Stage: Public
- Total Funding till date: $160M
- Employee Count: 10 - 49 as on Mar 01, 2026
- Investors: Janus Henderson Investors, Maverick Ventures and 21 Others
- Latest Funding Round: Series D, Sep 25, 2020, $*****
- Highlight: Public
4. Step Pharma
Developer of targeted oncology therapies inhibiting CTPS1 for cancer treatment. The company focuses on creating selective, orally bioavailable drugs for blood cancers and solid tumors. Their lead asset is in clinical development for lymphoma, ovarian cancer, and essential thrombocythaemia. Future development may include treatment regimens for solid tumours.
Key facts about Step Pharma
- Founded Year: 2014
- Location: Saint-Genis-Pouilly (France)
- Annual Revenue: €0 - €1M as on Dec 31, 2020
- Stage: Series C
- Total Funding till date: $95.7M
- Employee Count: 16 as on Aug 31, 2026
- Investors: Kurma Partners, Pontifax and 9 Others
- Latest Funding Round: Grant (prize money), Feb 19, 2026, $*****
- Highlight: Editors' Pick
Gesynta Pharma is developing oral therapies for treating chronic inflammatory conditions. The lead candidate of the company GS-248 is used for treating niche inflammatory indications. It's in the preclinical stage. It acts by inhibiting selective mPGES-1(microsomal prostaglandin E-synthase-1).
Key facts about Gesynta Pharma
- Founded Year: 2017
- Location: Solna (Sweden)
- Stage: Series B
- Total Funding till date: $31.1M
- Employee Count: 24 as on Aug 31, 2026
- Investors: Hadean Ventures, Industrifonden and 2 Others
- Latest Funding Round: Series B, Sep 16, 2020, $*****
- Highlight: Editors' Pick
Hadean Ventures' Year-on-Year Investment Trends
Hadean Ventures has invested in 21 companies over the last 8 years, with an average of 2 new investments annually in the last 5 years. In 2025, it made 4 investments, while as of Sep 2026, it has made 1 investment in this year. Its most recent first time investment was in Kasvu Therapeutics and most recent follow-on round was in TargED.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 0 | 1 |
2025 | 1 | 3 | 4 |
2024 | 1 | 0 | 1 |
2023 | 2 | 1 | 3 |
2022 | 4 | 0 | 4 |
2021 | 3 | 1 | 4 |
2020 | 5 | 0 | 5 |
2019 | 2 | 0 | 2 |
2018 | 2 | 0 | 2 |
Hadean Ventures' Investments by Stage
Hadean Ventures has made 10 investments in Series A stage with an average round size of $41.8M, 5 investments in Series B stage with an average round size of $37.9M and 2 investments in Series D stage with an average round size of $54.2M.Stage of entry | No. of Investments |
|---|---|
Series A | 10 |
Series B | 5 |
Series D | 2 |
PE | 1 |
Post IPO | 1 |
Others | 2 |
Note: We have considered here, only first round of investments
Hadean Ventures' Investments by Sector
Hadean Ventures has a diverse portfolio, with companies operating in the Life Sciences, HealthTech, High Tech, Enterprise Applications and Consumer. Notably, it has invested in 21 Tech companies, 18 Enterprise (B2B) companies, 5 Software companies and at least 4 companies focusing on Social impact.Sector | No. of Investments |
|---|---|
Life Sciences | 20 |
HealthTech | 3 |
High Tech | 3 |
Enterprise Applications | 2 |
Consumer | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Hadean Ventures' Investments by Geography
Hadean Ventures has made most investments in Sweden (4), followed by Germany where it has made 3 investments.Country | No. of Investments |
|---|---|
Sweden | 4 |
Germany | 3 |
Norway | 3 |
Austria | 2 |
Finland | 2 |
Others | 7 |
Note: We have considered here, only first round of investments
Hadean Ventures' recent investments
Hadean Ventures has made 1 investments in 2026 so far - Kasvu Therapeutics.Here are the most recent investments by Hadean Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 24, 2026 | Finland | Series C | 5082 | [+5] | |
Dec 18, 2025 | Netherlands | Series A | 1403 | ||
Oct 15, 2025 | France | Series C | 4390 | [+5] | |
Sep 17, 2025 | Spain | Series B | 1603 | [+6] | |
Jul 09, 2025 | United States | Series A | 9808 | [+7] |
IPOs and Publicly Listed companies in Hadean Ventures' Portfolio
2 of Hadean Ventures' portfolio companies have become public. Oncoinvent got listed on the Euronext Exchange (Euronext), in Dec 2024 at marketcap of $14.8M and Galecto Biotech got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $369M.Here are Hadean Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 13, 2024 | May 19, 2020 | Series B | 5536 | |
Oct 29, 2020 | Sep 25, 2020 | Series D | 2855 |
Acquired companies in Hadean Ventures' Portfolio
5 companies from Hadean Ventures' portfolio have been acquired. The most recent acquisition was Saga Diagnostics in Apr 2026 by Foundation Medicine for $*****.Here are Hadean Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Apr 16, 2026 | Jun 11, 2019 | Series A | 5549 | |
Feb 10, 2025 | Jun 03, 2022 | Post IPO | 3417 | |
Mar 25, 2024 | Aug 25, 2021 | Series B | 2527 | |
Jun 29, 2023 | Dec 07, 2021 | Series A | 7904 | |
May 26, 2020 | Sep 18, 2019 | Series D | 9990 |
_1581929172265.png?devicePixelRatio=2&height=20&width=20){kind=logo}
Team profile of Hadean Ventures
Hadean Ventures has a team of 13 members including 4 Partners and 1 Venture Partner located in Norway, Austria and 1 more location. Hadean Ventures' team does not sit on the board of any company as of now.Here is a list of top team members in Hadean Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Ebenfurth | - | ||
Partner | Oslo | - | ||
Partner | Stockholm | - | ||
Partner | Norway | - | ||
Venture Partner | Vienna | - |
Co-investors of Hadean Ventures
Over the past 8 years, 128 investors have co-invested in Hadean Ventures's portfolio companies. This includes funds and angels.
- Invested before Hadean Ventures: Europa, HTGF and 61 others have invested in rounds before Hadean Ventures. There are 5 companies where Europa has invested before Hadean Ventures and 3 companies where HTGF has invested before Hadean Ventures.
- Top Co-investors of Hadean Ventures: 56 investors entered a company along with Hadean Ventures. These include investors like Sunstone (3 companies).
- Invested after Hadean Ventures: A total of 9 investors have invested in Hadean Ventures's portfolio after their investments. Top Investors include Europa (2 companies), Segulah Medical Acceleration (1 company) and V-Bio Ventures (1 company).
Recent News related to Hadean Ventures
•
•
•
ARTHEx Biotech Raises $87M in Series B Extension to Advance ATX-01 ProgramPR Newswire•Sep 17, 2025•Bpifrance, ARTHEx, InVivo, AdBio partners and 6 others
•
BerGenBio ASA Announces Fully Underwritten Rights Issue to Raise Approximately NOK 130 MillionCision•Jul 01, 2025•BerGenBio, Oncoinvent, ABG Sundal Collier, DNB and 4 others
•
Announcement of fully underwritten rights issuePR Newswire•Jul 01, 2025•BerGenBio, Oncoinvent, ABG Sundal Collier, DNB and 4 others
•
BerGenBio announces fully underwritten rights issue for NOK 130 million after Oncoinvent ASA mergerDagens industri•Jul 01, 2025•Hadean Ventures, Linc, BerGenBio, Oncoinvent
•
Gesynta Pharma Receives $27 M For Endometriosis Novel Therapy DrugForbes•Feb 13, 2025•Gesynta Pharma, Innovestor, Amboy Street Ventures, Foreground Capital and 18 others
•
Oncoinvent ASA announces oversubscribed private placementDagens industri•Dec 05, 2024•Oncoinvent, Carnegie Investment Bank, DNB, Hadean Ventures and 3 others
•
SciRhom GmbH closes €63m Series A financingEuropean Biotechnology•Jul 11, 2024•SciRhom, Andera Partners, Kurma Partners, Hadean Ventures and 4 others
•
Scirhom targeting iRhom2 in autoimmune disease with €63M series ABioWorld•Jul 09, 2024•SciRhom, Andera Partners, Kurma Partners, Hadean Ventures and 5 others
